Investment Research Radio

Investment Research Radio interviews the most exciting up and coming companies both private and publicly traded. While being sector agnostic there is a focus on clean technologies, blockchain and being on top of the major trends which are changing the world around us.

Investment Research Radio is a business podcast hosted by Unknown Host, with 53 episodes on record and a Required Pod Score of 80.

Unknown Host hosts Investment Research Radio, a business show with 53 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #5

  Entirety Bio with CEO Jake Edick

  Sep 21, 202624 minS9

  Jake Edick, Entirety Biomedical: Reinventing Bioabsorbable Implants with Curasorb In this episode of Investment Research Radio, I sit down with Jake Edick, founder of Entirety Biomedical, to explore the future of medical implants and the company's Curasorb platform, a next generation approach to bioabsorbable orthopedic hardware. Traditional permanent implants, including titanium hardware, can provide the structural support surgeons need, but they can also remain in the body long after their job is done. Entirety Biomedical is developing a different approach: implants designed to provide temporary mechanical support and then gradually resorb as the body heals. Jake takes us inside the technology behind Curasorb, including Entirety's work with magnesium and its decision to pursue a non coated magnesium implant. We discuss what differentiates the platform from other bioabsorbable implant technologies and how the company believes its approach could create value for both surgeons and patients. We also discuss the company's regulatory and clinical development pathway, the applications Entirety is pursuing, its commercialization strategy, and the opportunity Jake sees for bioabsorbable implants across orthopedic surgery. Jake recently led Entirety Biomedical through its seed financing, so we also talk about what the company is using the capital to accomplish, the milestones ahead, and what it will take to move from promising technology toward clinical and commercial adoption. In this episode we discuss: • Jake's background in medical devices and biomaterials • The limitations of permanent titanium hardware • The problem Entirety Biomedical was created to solve • The Curasorb bioabsorbable implant platform • Magnesium as an implant material • Why Entirety is developing a non coated magnesium implant • How Curasorb differs from other bioabsorbable technologies • Potential benefits for patients and surgeons • FDA and clinical development milestones • Target applications and commercialization strategy • Entirety Biomedical's recent seed financing • The company's growth plans and upcoming milestones • Jake's five year vision for Entirety Biomedical • The broader opportunity in bioabsorbable medical devices https://www.entiretybio.com

  ListenShow Notes
• 

  Episode #4

  Graphene Manufacturing Group with CEO Craig Nichol

  Aug 21, 2026—S9

  Ray Crowley Interviews Craig Nicol, CEO of Graphene Manufacturing Group In this episode of Investment Research Radio , Ray sits down with Craig Nicol, Founder, CEO and Managing Director of Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTC: GMGMF) (Frankfurt: 0GF), to discuss the evolution of GMG from a graphene producer into a vertically integrated advanced materials and energy technology company. The conversation explores five interconnected assets and potential revenue streams built around GMG's proprietary graphene platform: 1. Graphene Raw Material Craig explains GMG's proprietary graphene manufacturing technology and the recent commissioning of its Gen 2.0 production plant, designed to produce up to 10 tonnes of graphene annually once fully optimized. The in-house production capability gives GMG control over material quality, supply and cost while providing the foundation for its downstream products. 2. THERMAL-XR® The discussion then moves to GMG's commercial energy savings business. THERMAL-XR® is a graphene enhanced coating designed to improve heat transfer and protect HVAC and industrial heat exchange equipment. With US EPA approval, North American distribution through Nu-Calgon and record June 2026 sales orders exceeding A$400,000, this represents GMG's most immediate commercial revenue opportunity. 3. G® LUBRICANT Ray and Craig discuss GMG's graphene lubricant additive, designed to reduce friction, fuel consumption and emissions in engines and other industrial applications. GMG has reported independently verified fuel efficiency improvements of up to 8.4% in diesel engine testing. The opportunity is to build recurring product revenue through distributors and industrial customers. 4. SUPA G® Battery Material The fourth layer of the business is GMG's proprietary graphene slurry for lithium ion batteries. Rather than having to manufacture an entire battery, SUPA G® potentially allows GMG to sell a specialized material into existing battery manufacturing supply chains. This creates another pathway to monetize the graphene platform while battery manufacturers evaluate performance improvements. 5. G CELLS™ Graphene Aluminium Ion Battery Finally, the conversation looks at GMG's highest value and longest term opportunity: its graphene aluminium ion battery technology. Developed with the University of Queensland and supported by Australian government funding, the technology is being advanced toward larger cells, manufacturing processes and eventual commercialization. This could ultimately move GMG from selling materials and additives into supplying an entire next generation energy storage technology. Ray and Craig discuss how these five assets create a layered commercialization strategy: produce the raw material, sell graphene enabled products, supply graphene into other manufacturers' batteries, and ultimately develop GMG's own battery technology. The conversation also looks ahead to GMG's expansion into North America and Europe, additional industrial applications, data centre cooling, strategic partnerships and the potential for modular graphene production facilities. Craig explains how the company's near term focus is converting commercial product adoption into revenue while continuing to invest in the much larger battery opportunity. The central investment story is therefore not simply graphene production alone. It is GMG's attempt to build an integrated materials platform where one proprietary graphene manufacturing capability supports multiple products, and multiple revenue streams.

  ListenShow Notes
• 

  Episode #3

  Nuvo Interview With Co-Founder and CEO Laurence Klein

  Jun 9, 202628 minS9

  In this episode, we sit down with Laurence Klein, Co-Founder and CEO of Nuvo, to explore how the FDA cleared INVU™ platform is reshaping maternal fetal surveillance and redefining the standard of care for pregnancy. Laurence traces the company's mission to replace episodic, clinic bound monitoring with continuous, medical grade prenatal care delivered at home or at work — and explains how that vision is now meeting a rapidly expanding commercial market. We cover: The Genesis of Nuvo — How a pregnancy wearable idea became a mission to decentralize prenatal care and put clinical-grade monitoring in the hands of expectant mothers wherever they are. The Biosensing Architecture — How INVU™'s passive array of ECG and PCG surface sensors, paired with cloud-based AI, achieves medical-grade fetal monitoring without active ultrasound — and what that means for accuracy, wearability, and scale. The Market Opportunity — Why the convergence of rural care gaps, urban lifestyle demands, and remote monitoring is creating a structural shift — not just a product category. Capital Strategy & What's Next — Deployment priorities following their Series A, the role of generative data pipelines in expanding clinical intelligence, and what institutional investors should be watching heading into the next growth round. Essential listening for anyone following the intersection of deeptech medical devices, digital health infrastructure, and AI-driven diagnostics.

  ListenShow Notes
• 

  Episode #2

  Diamond Quanta with CEO Adam Khan

  Apr 13, 202626 minS9

  <p >In this episode of Investment Research Radio, we sit down with Adam Khan, CEO of Diamond Quanta, to explore one of the most exciting frontiers in next generation computing and semiconductors. He is actively catalyzing silicon valley into diamond valley.</p> <p >Diamond Quanta is pioneering breakthroughs in semiconductor and quantum technologies using diamond based materials, with the potential to redefine computing and electronics. Adam shares the company's vision, the science behind their approach, and how their platform could unlock real world quantum advantage across multiple industries.</p> <p >We dive into:</p> The unique role of diamond in...

  ListenShow Notes
• 

  Episode #1

  Nickolai Vysokov CEO Interview of Brain Patch

  Jan 26, 202618 minS9

  <p > In this episode, we sit down with Dr. Nickolai Vysokov, PhD Neuroscience, CEO to unpack the story behind Brain Patch and how the company has evolved from a research driven idea into a finished, commercial ready neurotech product.</p> <p > We cover where BrainPatch is today, including real world traction such as its retail debut at Selfridges in London and availability through US channel partner Caputron, plus a clear plan to scale manufacturing and sales as they raise their next round of capital.</p> <p > Nickolai also shares the scientific foundation behind the product and BrainPatch's growing credibility in...

  ListenShow Notes

Recent guests on Investment Research Radio. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.